SCHEMBL23930468

SCHEMBL23930468

CC(C(N)=O)N(c1ccc(F)cc1)c1nc(N)c(C(=O)c2cc(C(=O)NCCOC(F)(F)F)no2)s1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 5/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
POLB P06746 3/20 0.35
NPC1 O15118 3/20 0.34
TP53 P04637 3/20 0.34
RAB9A P51151 3/20 0.34
LMNA P02545 1/20 0.34
HTT P42858 1/20 0.34
HIF1A Q16665 1/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
HDAC3 O15379 2/20 0.33
HDAC4 P56524 2/20 0.33
HDAC1 Q13547 2/20 0.33
HDAC7 Q8WUI4 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC10 Q969S8 2/20 0.33
HDAC11 Q96DB2 2/20 0.33
HDAC8 Q9BY41 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30210870 1.00 HDAC6 (0.35) HDAC6SMN1; SMN2POLBNPC1TP53
SCHEMBL30210934 0.94 HDAC6 (0.35) HDAC6SMN1; SMN2POLBNPC1TP53
SCHEMBL23930548 0.94 HDAC6 (0.35) HDAC6SMN1; SMN2POLBNPC1TP53
SCHEMBL30210895 0.89 POLB (0.37) HDAC6SMN1; SMN2POLBNPC1TP53
SCHEMBL23930596 0.89 POLB (0.37) HDAC6SMN1; SMN2POLBNPC1TP53
SCHEMBL25199172 0.86 SMN1; SMN2 (0.38) HDAC6SMN1; SMN2POLBNPC1TP53
SCHEMBL31411943 0.86 SMN1; SMN2 (0.38) HDAC6SMN1; SMN2POLBNPC1TP53
SCHEMBL23930498 0.86 MAPT (0.38) SMN1; SMN2POLBNPC1TP53RAB9A
SCHEMBL30210848 0.86 MAPT (0.38) SMN1; SMN2POLBNPC1TP53RAB9A
SCHEMBL23930566 0.86 SMN1; SMN2 (0.37) HDAC6SMN1; SMN2POLBNPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4139287-B1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AG (DE) 2025-02-26 EP claimed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US claimed
EP-4139287-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION Bayer Aktiengesellschaft (DE) 2023-03-01 EP claimed
CN-115697979-A Substituted aminothiazoles as DGKZETA inhibitors for immune activation 拜耳公司 2023-02-03 CN claimed
WO-2021214020-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2021-10-28 WO claimed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION BAYER AKTIENGESELLSCHAFT (DE) 2023-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167103-A1 SUBSTITUTED AMINOTHIAZOLES AS DGKZETA INHIBITORS FOR IMMUNE ACTIVATION DGKZ, DGKA, DGKG HDAC6 3143/4885SMN1; SMN2 4815/4885POLB 3055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.